Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel
NASDAQ:DRTS

Alpha Tau Medical Q3 2025 Earnings Report

Alpha Tau Medical logo
$7.39 -0.14 (-1.85%)
Closing price 03:59 PM Eastern
Extended Trading
$7.51 +0.12 (+1.61%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Alpha Tau Medical EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Alpha Tau Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alpha Tau Medical Announcement Details

Quarter
Q3 2025
Date
11/20/2025
Time
Before Market Opens
Conference Call Date
Thursday, November 20, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Alpha Tau Medical's Q1 2026 earnings is estimated for Monday, May 18, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, May 19, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Alpha Tau Medical's Q3 2025 Earnings ReleaseEarnings Release
(6-K)

Alpha Tau Medical Earnings Headlines

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
May 5 at 9:14 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287848/0/en/alpha-tau-announces-upcoming-podium-presentation-at-the-ahns-12th-international-conference-on-head-and-neck-cancer-showcasing-study-results-of-alpha-dart-head-and-neck-cancer-combi.html
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
May 4 at 9:17 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3286810/0/en/alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile-observed-in-alpha-dart-pancreatic-cancer-trials-presented-at-ddw-2026.html
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
May 5 at 1:00 AM  |  Weiss Ratings (Ad)
Alpha Tau Medical (NASDAQ:DRTS) Sees Unusually-High Trading Volume - Here's What Happened
May 3 at 4:51 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30755817
Head-To-Head Review: Alpha Tau Medical (NASDAQ:DRTS) versus Treace Medical Concepts (NASDAQ:TMCI)
May 2 at 5:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30754138
Alpha Tau Medical Ltd. Announces Acceptance of Abstract at ASCO Annual Meeting Highlighting Alpha DaRT's Efficacy in Pancreatic Cancer
April 27, 2026  |  quiverquant.comQ
See More Alpha Tau Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email.

About Alpha Tau Medical

Alpha Tau Medical (NASDAQ:DRTS) is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors. Alpha DaRT implants release alpha-emitting atoms that diffuse a few millimeters into the tumor, providing localized radiation doses that have shown promising preclinical and early clinical anti‐tumor activity. Alpha Tau Medical has secured Breakthrough Device designation from the U.S. Food and Drug Administration for certain cancer types and is advancing its pipeline through multi‐center trials in Europe and Israel.

Alpha Tau Medical collaborates with major oncology centers and academic institutions to conduct its clinical programs and to explore combination approaches with immunotherapies and other treatment modalities. The company has expanded its operational footprint beyond Israel, engaging regulatory and commercial partners in Europe while preparing for potential U.S. market entry. Through its focused R&D efforts and strategic alliances, Alpha Tau Medical seeks to establish alpha‐particle brachytherapy as a new standard of care for patients with challenging solid tumors.

View Alpha Tau Medical Profile
Earnings Tools